OncoMatch/Clinical Trials/NCT06503263
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Is NCT06503263 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Zanubrutinib plus Lenalidomide as Maintenance Therapy for diffuse large b-cell lymphoma.
Treatment: Zanubrutinib plus Lenalidomide as Maintenance Therapy — The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Demographics
Prior therapy
Must have received: chemotherapy — induction
Patient has recieved complete remission and has completed planed courses of chemotherapy
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (≥ 1 x 10^9/L if bone marrow involvement by lymphoma); Platelet ≥ 75 x 10^9/L (≥ 50 x 10^9/L if BM involvement by lymphoma); Hemoglobin ≥ 8 g/dL
Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10^9/L (≥ 1 x 10^9/L if bone marrow (BM) involvement by lymphoma)；Platelet ≥ 75 x 10^9/L (≥ 50 x 10^9/L if BM involvement by lymphoma)； Hemoglobin ≥ 8 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06503263 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify